Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetic Neuropathy, Painful

In brief

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy

Key facts

Study ID

NCT00381719

Run by

Allergan

People needed

330

Starts

2006-10-01

Expected to finish

2007-11-01

Last updated by the study team

2008-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of diabetic peripheral neuropathy
• Moderate to severe neuropathic pain

You may not qualify if…

• Any other uncontrolled disease
• Pregnant or nursing females

Where it is running

• Study site — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.